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Abstract
Objective: To quantify marine food product consumption and EPA1DHA intake
among Quebecers, and to compare the results with the most recent recommen-
dations.
Design: Data were obtained from a representative cross-sectional telephone
survey (June 2006). Intakes of marine food product species and EPA1DHA were
estimated from a validated FFQ on the consumption of marine food products
during the previous month. Prevalence of fish oil consumption in the last 6
months was also assessed.
Setting: Province of Quebec (Canada).
Subjects: A representative sample (n 1001) of adults in the province of Quebec. Of
these, eight were excluded from the present analysis (n 993).
Results: Mean and median EPA1DHA intakes for all participants were estimated to
be 291mg/d (SEM 11) and 207mg/d, respectively. 85?0% (95% CI 82?7, 87?3) of
Quebecers had an EPA1DHA intake lower than 500mg/d, which is the amount
internationally recommended for the prevention of CVD. Mean and median DHA
intakes among women of childbearing age (n 128, 18–34 years) were estimated to
be 169mg/d (SEM 17) and 126mg/d, respectively. Of these women, 27?7% had a
daily intake .200mg DHA and 15?9% had an intake .300mg DHA. We noted that
13% of Quebecers take $1 capsule of fish oil/d.
Conclusions: Consumption of marine food products and EPA1DHA among
Quebecers clearly appears to be lower than international recommendations. Since
EPA1DHA confer health benefits and may reduce health costs, strategies to increase
their consumption should be implemented to improve public health in Quebec.
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Decreasing intake of n-3 fatty acids and increasing intake
of n-6 fatty acids are widely considered to be contributing
to the rising incidence of many chronic, degenerative
diseases(1). However, it has been suggested that n-3 from
fish and seafood might be the more important factor in
total n-3/total n-6 ratios, and that the utilisation of ratios is
mathematically problematic(2). Fish and seafood contain
two n-3 long-chain (LC) PUFA – EPA and DHA – both of
which appear to be beneficial for the prevention or
treatment of CVD(3) and inflammatory disorders, such as
rheumatoid arthritis(4). Although humans are technically
capable of endogenously synthesising EPA and DHA
from the n-3 precursor in plants (a-linolenic acid; a-LNA),
this conversion is a very inefficient way of increasing
DHA in tissues(5). Therefore, in general, EPA and DHA
concentrations in blood reflect habitual dietary EPA and
DHA intake(6).
In CVD prevention, it has been proposed(7) that inter-
ventions should initially concentrate on lifestyle factors
linked to CVD risk factors (hypertension, hypercholes-
terolaemia or diabetes)(8) or nutritional factors for which
there is evidence of a protective effect, such as the con-
sumption of fish, fish oil or marine food products(3).
Several organisations recommend n-3 LC PUFA to reduce
CVD risk, especially sudden death and death from CHD
in adults(3,9). n-3 LC PUFA may also have beneficial out-
comes on mental health(10). A recent evidence-based
review of international recommendations for LC n-3 fatty
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acids indicates that an intake of 500mg/d of EPA and
DHA reduces CVD risk(11). This daily EPA and DHA intake
has been suggested by several health agencies world-
wide (Table 1).
The intake of n-3 LC PUFA during pregnancy and lac-
tation is also associated with beneficial effects for mothers
and the mental development of their children(10,12). Since
the fetus is unable to synthesise sufficient DHA for
the development of its nervous system, it depends on
the mother for DHA(13). Preformed DHA is preferred for
infants and is obtained prenatally via the placenta, post-
natally from breast milk, fat stores, supplemented formula
and, later, from foods(14,15). Breast-feeding is the pre-
ferred method of infant feeding(16). The DHA content of
breast milk is strongly positively associated with the fre-
quency of fish intake and n-3 LC PUFA intake(12,16).
However, supplementation of breast-feeding mothers
with the DHA precursor a-LNA (10?7 g/d) from flaxseed
oil does not increase DHA in breast milk(17). Recently, a
European collaborative group indicated that providing
EPA and DHA at 1–2?7 g/d to pregnant and lactating
women had no significant adverse effects(18). To assure
sufficient DHA for fetal and maternal tissue DHA accre-
tion, the recommended daily intake of DHA during
pregnancy and lactation has been set at 200mg by the
Perinatal Lipid Intake Working Group (PeriLip)(18), and
300mg by the International Society for the Study of Fatty
Acids and Lipids (ISSFAL)(19).
In 1990, the consumption of fish and n-3 LC PUFA did
not represent a significant part of the diet of Quebe-
cers(20,21). Between 1990 and 1992, Sante´-Que´bec, an
organisation of the Que´bec Ministry of Health and Social
Services, conducted a series of health surveys among
southern Quebecers, James Bay Cree (Northwestern
Quebec) and Inuit of Nunavik (Northern Quebec). Data
from 24 h dietary recalls revealed that on the day before
each survey, mean daily consumption of fish was 13 g
for Southern Quebecers, 60 g for James Bay Cree, and
131 g for the Inuit of Nunavik. The daily fish intake of
the Cree and Inuit populations provided ,700–900 and
2115mg of EPA1DHA, respectively(21). However, fish
intake among Southern Quebecers provided ,200mg/d
of EPA1DHA, a level also observed in the USA(22). In
parallel, a natural health product that is becoming more
popular in the Canadian population is fish oil or sup-
plements containing EPA and DHA. Indeed, according to
the 2000–2001 Canadian Community Health Survey
(CCHS) results, the proportion of Canadians who took
fish oil was 9?4%(23).
Much scientific and lay publicity concerning the benefits
of n-3 LC PUFA intake has circulated worldwide since
Sante´-Que´bec’s health surveys in the 1990s(20,21). Although
EPA and DHA have recently gained in popularity, little is
known about their actual intake by Quebecers. From a
public health standpoint, it was therefore important to
know the actual EPA1DHA intake of the Quebec popu-
lation. To our knowledge, no other recently published
studies have attempted to quantify fish consumption and
dietary EPA1DHA intake among Quebecers. The primary
objective of the present study was, therefore, to analyse
marine food product consumption and EPA1DHA intake
among a representative sample of adults from the province
of Quebec, and to compare these values with the most
recent recommendations (Table 1).
Subjects and methods
Study design and participants
Data were obtained from a representative cross-sectional
telephone survey (n 1001) by random digital dialling for
the selection of one adult (.18 years) per household.
During the telephone survey, participants were asked to
complete a validated FFQ about marine food products(6).
Telephone interviews were conducted by trained inter-
viewers from the largest independent market research
Table 1 International recommendations for EPA and DHA
Source (date) and references
Recommendations
EPA and DHA (mg/d)
UK Committee on Medical
Aspects of Food Policy
(1994)(24)
100–200
FNB-IOM, USA (2002)(25) 130–270*
Eurodiet (2000)(26) 200
Health Council of the
Netherlands (2001)(27)
200
PeriLip(18) Pregnancy and lactation .200
DHA
ANC (France) (2001)(28) 450 (DHA, 110–120)
NHMRC of Australia (2005)(29) 430- (women), 610- (men)
WHO/FAO (2003)(30) 400–1000 (1–2 fish meals/week)
UK Scientific Advisory
Committee on Nutrition
(2004)(31)
Minimum two fish meals/week
(one fatty fish) E450
ISSFAL Workshop (2004)(32) $500
ADA/DC (2007)(33) Two fish meals/week (fatty fish),
8 oz cooked fish E500
AHA/AHA Nutrition Committee
(2002, 2006)(3,34)
Two fish meals/week (fatty fish)
E430–570
ISSFAL Expert Workshop 650
(1999)(35) Pregnancy and lactation .300
DHA
NATO Workshop (1989)(36) 800
British Nutrition Foundation
(1992)(37)
1100-
AHA (2002)(3) 1000 (2nd CHD prevention)
European Society of
Cardiology (2003)(38)
1000 (2nd CHD prevention)
a-LNA, alpha-linolenic acid (18 : 3n-3); ADA, American Dietetic Association;
AHA, American Heart Association; ANC, Apports nutritionnels conseille´s;
DC, Dietitians of Canada; DHA (22 : 6n-3); EPA (20 : 5n-3); FNB-IOM, Food
and Nutrition Board of the Institute of Medicine of the National Academies of
Science; ISSFAL, International Society for the Study of Fatty Acids and
Lipids; NATO, North Atlantic Treaty Organization; NHMRC, National Health
and Medical Research Council; PeriLip, Perinatal Lipid Intake Working
Group.
*EPA and DHA can contribute up to 10 % of total n-3 intake and, therefore,
up to this percentage can contribute toward the adequate intake of a-LNA
(18 : 3n-3) (1?3–2?7 g/d).
-n-3 long-chain PUFA: EPA, DHA, DPA (docosapentaenoic acid, 22 : 5n-3).
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firm in Canada – Le´ger Marketing (Montre´al). Sampler
software (ASDE Survey Sampler Inc., Gatineau, QC,
Canada) selected the random sampling population. The
margin of error for the 95% CI of this survey was 63?4%.
The response rate was 56?9%. Among the 1001 participants
interviewed, eight gave aberrant answers to questions on
marine food product consumption (e.g. twenty meals of
226 g or 8oz/week) and were, therefore, excluded from the
present analysis (n 993). Gender, age, occupation, level of
education, income and region were available for each
respondent. Furthermore, a weight was established for
each respondent according to the latest data from Statistics
Canada regarding region, maternal language, gender and
age. Therefore, the data presented in the present paper
were obtained from weighted data and represented the
adult population of Quebec as a whole.
Assessment of marine food product intake
Data on the consumption of marine food products were
generated by completion of a validated FFQ, which
evaluated marine food product intake within the last
month. Validation and more details of the FFQ have been
given elsewhere(6). Briefly, the FFQ was validated by
measuring the relationship between baseline EPA1DHA
intake assessed by this FFQ and EPA1DHA concentra-
tion in red blood cells (RBC) among a sample of middle-
aged women (n 65) participating in a randomised clinical
trial. Analyses indicated that baseline EPA1DHA intake,
measured by our FFQ, correlated reasonably well
(Spearman’s r5 0?42, P5 0?0005) with EPA1DHA con-
centration in RBC at baseline. The FFQ had two principal
questions. The first question referred to the portion size
of fish consumed: ‘In general, what is the portion size that
corresponds best to your habitual consumption when you
eat fish?’ The second question of the FFQ was aimed at
knowing the frequency of marine food products con-
sumed: ‘Based on your food consumption of the last
month, how many times did you consume the following
marine food products?’ The questionnaire included seven
groups of marine food products: (i) oily fish (fresh or
canned salmon, herring, mackerel, sardines); (ii) canned
tuna; (iii) trout or halibut; (iv) white fish (sole, rockfish,
haddock, cod, etc.); (v) molluscs (mussels, oysters, clams,
scallops); (vi) crustaceans (shrimps, crabs, lobsters, etc.);
(vii) imitation crab. Based on the 2005 Canadian Nutrient
File of Health Canada(39), each of these groups of marine
food products was assigned an amount of EPA and DHA.
A question concerning fish oil consumption was also
added to the FFQ: ‘Over the last 6 months, what was your
fish oil supplement consumption (capsules containing
marine omega-3 fatty acids)?’
Statistical analysis
The statistical distribution of marine food product and
EPA1DHA intakes was found to be skewed. Therefore,
log transformation was undertaken to compare marine
food product and EPA1DHA intakes relative to socio-
economic characteristics. Arithmetic means were also
calculated to facilitate comparisons with other studies.
Student’s t test was only used to compare EPA1DHA
intake between genders. An ANOVA test with Bonferroni
correction for multiple comparisons compared EPA1
DHA intake according to other participant characteristics
(age, occupation, level of education and income). Geo-
metric mean values (95% CI) were presented for com-
parisons according to participants’ characteristics. The
x2 test was performed to compare the proportion of
Quebecers who had an intake lower than the interna-
tional recommendation for CVD protection (500mg
EPA1DHA/d), according to gender. Since DHA intake is
a key nutrient during pregnancy and lactating periods, we
extracted data on this parameter among women of
childbearing age (n 128, 18–34 years). DHA intake of
these women was compared to the daily intake recom-
mended during pregnancy and lactation by PeriLip
(.200mg/d)(18) or ISSFAL (.300mg/d)(19). Statistical
analyses were conducted with the SAS program for
Windows v?9 (SAS Institute Inc., Cary, NC, USA). Differ-
ences between groups and associations were considered
significant at P# 0?05 (bilateral).
Results
Demographic characteristics of the study respondents are
presented in Table 2. Among the 993 adults who responded
to the survey, forty-two had missing information on portion
size, leaving 951 subjects for the estimation of intakes of
marine food products and EPA1DHA. Of these, a total of
109 subjects (11?5%) were non-consumers of marine food
Table 2 Characteristics of the study subjects (n 993)
Characteristics %
Female 51?9
Age (years)
18–24 12?2
25–44 39?0
45–64 32?4
$65 16?3
Family income in 2005
,$19 999 11?7
$20 000 to $39 000 26?1
$40 000 to $99 000 36?2
$$100 000 10?8
Don’t know/refuse to answer 15?3
Education
Primary school (,7 years) 6?1
Secondary school (8–12 years) 36?1
College degree 24?4
University degree 33?4
Occupation
Student 8?5
Unemployed 3?1
At home 7?2
Workers 59?3
Retired 21?9
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products. Mean intakes (g/d) of oily fish, canned tuna,
trout or halibut, white fish, molluscs, crustaceans and
imitation crab were 12?0 (SD 16?4), 7?3 (SD 13?3), 3?6 (SD
8?3), 5?6 (SD 10?7), 1?6 (SD 4?0), 4?9 (SD 7?7) and 1?7 (SD
6?4), respectively. Their EPA1DHA contributions (mg/d)
were 179 (SD 244), 28 (SD 50), 34 (SD 77), 19 (SD 36), 8 (SD
20), 14 (SD 22) and 11 (SD 39), respectively. Total fish
intake was 28?4 g/d (SD 31?7) and contributed to an
EPA1DHA intake of 258mg/d (SD 307). The mean intake
of total marine food products was 36?6 g/d (SD 37?7).
However, the median intakes of oily fish, total fish and
marine food products were 7, 19 and 28 g/d, respectively.
Mean and median EPA1DHA intakes were estimated to
be 291mg/d (SD 328) and 207mg/d, respectively. The
geometric mean of EPA1DHA intake was 217mg/d
(95% CI 203, 232). EPA1DHA intakes were not statisti-
cally different between men and women (t8405 1?26,
P5 0?2097). However, the proportion of Quebecers who
had an intake ,500mg EPA1DHA/d was 85?0% (95%
CI 82?7, 87?3), and was higher among males (88?8%, 95%
CI 85?9, 91?7) than females (81?5%, 95% CI 78?0, 84?9)
(x25 10?0, P5 0?0015). EPA1DHA intakes increased
progressively with age (P trend5 0?0389), income (P
trend5 0?0020) and education (P trend5 0?0441) (data
not presented). No statistical differences (P. 0?05) were
noted for geometric means of EPA1DHA intake
according to age or education groups. Among people
with income ,$20 000, the geometric mean of EPA1
DHA intake was 151mg/d (95% CI 121, 188) and was
significantly lower (P, 0?05) – by about 79mg – com-
pared to other income classes.
Mean and median DHA intakes among women of
childbearing age (n 128) were estimated to be 169mg/d
(SD 198) and 126mg/d, respectively. The geometric
mean of DHA intake among these women (n 111) was
127mg/d (95% CI 104, 155). The proportions of women
of childbearing age who had adequate DHA intake, as
recommended by PeriLip (.200mg/d DHA) and ISSFAL
(.300mg/d DHA), were 27?7% (95% CI 20?4, 35?1%)
and 15?9% (95% CI 9?9, 21?9%), respectively.
The prevalence of fish oil capsule consumption (n 993)
was 20?7%, with 13% taking $1 capsule of fish oil/d. The
prevalence of fish oil consumption (x25 0?81, P5 0?369)
and taking $1 capsule of fish oil/d (x25 0?40, P5 0?529)
was not significantly different between men and women.
Among women, the rate of $1 capsule of fish oil/d was
three times higher among older compared to younger
women ($45 years5 19?1% v. ,45 years5 6?2%, P,
0?0001). However, this difference was not observed
among males ($45 years5 3?9% v. ,45 years5 9?8%,
P5 0?18). Among participants aged 45–64 years, the rate
of $1 capsule of fish oil/d was two times higher among
women than men (OR5 2?0, 95% CI 1?05, 3?79). The
weekly portions of each marine food category of the FFQ
that are needed to attain international recommendations
of 500mg/d of EPA1DHA are shown in Fig. 1.
Discussion
In a representative sample of adults in the province of
Quebec, we estimated mean and median EPA1DHA
intakes to be 291mg/d and 207mg/d, respectively. Sev-
eral organisations have recognised the importance of
consuming marine food products as well as n-3 LC PUFA
to reduce the risks of CVD. In its recent revision of diet
and lifestyle recommendations (2006), the American
Heart Association urged the consumption of two fish
meals per week (preferably fatty fish), which is equivalent
to 430–570mg of EPA and DHA daily(34). A review of the
risks and benefits of fish consumption suggested that a
modest intake of fish (1–2 fish meals/week), especially
Crustaceans
White fish
Canned tuna
Molluscs
Imitation crab
Trout and halibut
Oily fish
Weekly portionsa (number/week) needed to attain 500 mg EPA +DHA/d
0 1 2 3 4 5 6 7 8 9 10 11
Fig. 1 Quantity of weekly portions* needed to attain the international recommendation of 500 mg EPA1DHA/d. This daily EPA and
DHA intake has been suggested by several health agencies worldwide (see Table 1) (*1 portion5113 g (4 oz) cooked; DHA,
22 : 6n-3; EPA, 20 : 5n-3)
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those rich in EPA and DHA, decreases the risk of CHD
death by 36%(40). Analysis of fifteen randomised clinical
trials indicates that n-3 LC PUFA reduce total mortality by
17%(40). A daily intake of E500mg of EPA and DHA has
been chosen by many organisations as a target for CVD risk
reduction(11). Only 15?0% of the Quebecers we surveyed
had a self-proclaimed EPA1DHA intake $500mg/d.
Moreover, the median intake of oily fish among these
Quebecers was 49 g/week, which is equivalent to about
one oily fish meal every 2 weeks. Compared to Western
populations, the Japanese CHD death rate is very low
and EPA1DHA intake is very high(41). In our population,
two fish meals/week is the target, whereas among the
Japanese, the reference group (the lowest) is often com-
prised of those who eat 1–2 fish meals/week.
Among the women of childbearing age we surveyed,
mean intake of DHA was 169mg/d (SEM 17), a result
agreeing with that of Innis and Elias who reported on
fifty-five pregnant women in British Columbia(42). They
administered an FFQ between weeks 28 and 35 of preg-
nancy, and noted a mean DHA intake of 160mg/d (SEM 20),
with 16% of women they surveyed consuming .300mg
DHA/d. Similarly, we observed that 15?9% of women of
childbearing age had a DHA intake.300mg/d, and 27?7%
had a DHA intake .200mg/d. Based on dietary intakes
from a 3 d food record among twenty pregnant women
from Ontario, Denomme et al. noted a mean DHA intake
of 82mg/d (SEM 33)(43). The third trimester of pregnancy is
a critical growth period that is highly susceptible to nutri-
tional insults(16). Clandinin et al. suggested that 80% of the
DHA present in the human brain at birth accumulates
during the third trimester(44). DHA levels in the brain
increase in parallel with rapid brain growth(45), from the
third trimester through the first years of life, and are closely
linked to the presence of DHA in the infant’s diet(15).
Combining our present results with two Canadian studies
among pregnant women(42,43), it seems clear that DHA
intake among women of childbearing age or pregnant
women in Canada is lower than what is recommended for
pregnancy and lactation. These findings indicate a need
for studies addressing the effects of low DHA intake on
pregnancy outcomes and infant neurodevelopment in
Canada.
To our knowledge, no other recently published studies
have attempted to quantify fish consumption and dietary
EPA1DHA intake among Quebecers. In our present
work, mean intakes of total fish and total marine food
products were 28?4 g/d and 36?6 g/d, respectively. In the
1990 Sante´-Que´bec survey among Quebecers, fish intake
was determined by FFQ administered by a nutritionist
during face-to-face interviews at home. The FFQ mea-
sured consumption during the month before the survey
and included only two fish items: fish and fried fish. Each
participant was asked to provide the usual frequency of
consumption and the usual portion size. The participants’
reported mean fish intake was 95 g/week during the
month before the survey. The median intake of total fish
consumed was 55 g/week. In the present study, median
intake of oily fish and total fish was 49 g/week and 134 g/
week, respectively. This divergence in results between
the 1990 survey and our present survey can probably be
explained by the proportion of non-consumers of fish
in the 1990 Sante´-Que´bec survey, which was 43?3% in
1990 but was only 11?5% in our survey. The different
results may also be due to the use of two very different
questionnaires. The FFQ in the present study evaluated
the consumption of seven categories of marine food
products, whereas the questionnaire in the 1990 Sante´-
Que´bec survey had only two questions, one of them on
fried fish. EPA1DHA in RBC, a biomarker of marine n-3
fatty acid consumption, correlates very well with the risk
of CHD death(46) and with human myocardial n-3 con-
centration(47). EPA1DHA intake measured by our FFQ
correlated reasonably well with EPA1DHA concentra-
tion in RBC (Spearman’s r5 0?42, P5 0?0005)(6).
In North America, an increasing number of persons are
turning to natural health products(48). Indeed, according
to 2000–2001 CCHS results, the proportion of Canadians
who took fish oil was 9?4%(23). In the present study, we
noted that 20?7% of participants consumed fish oil cap-
sules, with 13% ingesting$1 capsule of fish oil/d. Among
women, the rate of $1 capsule of fish oil/d was three
times higher among older compared to younger women,
but this difference was not observed among males. In the
CCHS, the prevalence of past 2 d natural health product
use was 1?5–2 times higher in women between the ages
of 36 and 75, than men of the same age group(23).
However, among participants aged 45–64 years, we noted
that the rate of $1 capsule of fish oil/d was two times
higher among women than men. This confirms the fact
that middle-aged women are important consumers of
natural health products(23). However, we did not ask
about the format or n-3 concentration of fish oil taken
and we were, therefore, unable to estimate EPA and DHA
intake from fish oil. Since 13% of the Quebecers we
surveyed take more than 1 fish oil capsule/d, the EPA1
DHA intake among some Quebecers is probably higher
than the level estimated by only the FFQ. In addition, the
dietary EPA and DHA intakes of Quebecers might be
higher than we estimated because a low level of those n-3
fatty acids might be provided by chicken and regular egg
consumption (an additional contribution of E30mg of
EPA1DHA/d)(39). Moreover, EPA1DHA intake may be
even higher if Quebecers consume food products, such as
eggs, yoghurts, milk, cheese and beverages, fortified with
these n-3 fatty acids.
Our study has a number of limitations. Data collection
by telephone survey is relatively quick and inexpensive,
but it has the problem of growing coverage and falling
response rates. Indeed, the major biases with telephone
surveys are observational errors (or sampling errors), such
as non-coverage bias, non-response bias (non-participation)
n-3 Fatty acid intake among Quebecers 67
and sampling bias(49). Because of the trend away from
fixed landlines to cellular phones, the non-coverage bias
is becoming a major problem in telephone survey
research. Even if ownership of cellular phones is high
among Quebecers (46%), most of these adults also have
landline telephone service (Le´ger Marketing, personal
communication). Indeed, 98–99% of Quebecers have a
fixed landline phone, and only 1% has no service at all. It
is generally accepted that the response rate to telephone
surveys is decreasing(50). Reports have indicated that for
response rates in the 40–70% range, non-response bias
does not appear to significantly affect survey esti-
mates(51,52). A comparison of non-responses in surveys
revealed that face-to-face situations had the highest
completion rate, telephone surveys, the next highest,
and mail surveys, the lowest(53). Our response rate was
56?9%. Moreover, our results were weighted according to
the latest Statistics Canada data to make the sample
representative of the adult Quebec population. Taken
together, these potential sampling errors are unlikely to
have seriously influenced our findings.
Other limitations could be attributed to the fact that our
FFQ has been validated in face-to-face interviews among
middle-aged women(6). However, conversion of a-LNA
to EPA or DHA has been suggested to be higher among
young women due to oestrogen(54). Nevertheless, if the
a-LNA conversion rate is likely higher among women
compared to men, it indicates that the relationship
between EPA1DHA intakes and RBC EPA1DHA con-
centrations might be at least equal, or superior, to that in
men. However, data from our validation study were self-
reported. Therefore, the results might be different since
distinct modes of administration of the FFQ were used.
Another limitation that affects every FFQ or any estimated
nutrient intake tool is the utilisation of nutrient databases
that might not adequately reflect temporal changes in
food composition(55). Moreover, dietary EPA and DHA
may vary considerably in the same fish species. We pre-
viously noted, that EPA1DHA in skinless fillets (100 g
raw) of farmed Atlantic salmon and rainbow trout ranged,
respectively, between 414–1460mg and 263–1334mg(56).
In addition, intakes of EPA and DHA can be very different
if consumers eat only skinless fillets or subcutaneous fat.
If the recommendation to consume two fish meals/
week is to become the norm in the Quebec population,
modifications of the food environment and public health
strategies are warranted. To reach the international
recommendation of 500mg of EPA1DHA/d, two meals
(113 g or 4 oz) per week of oily fish are required, whereas
nine meals of white fish would be needed (Fig. 1). Con-
sumption of fatty fish, such as salmon, herring, mackerel
or sardines, is the cheapest and easiest way to increase
EPA1DHA intake. However, a large proportion of the
population is unable or unwilling to consume EPA1DHA
from fish alone. In fact, only one-third of the participants
reported an oily fish intake of $1 meal/week. Alternative
strategies would be the intake of fish oil capsules or
increased intake of foods enriched with n-3 LC PUFA.
Even if fish oil capsules are associated with health ben-
efits(4,9,10) and with reduced health costs from secondary
CHD prevention(57,58), fish and seafood are still preferred
because they contain nutrients other than n-3 fatty acids
and, thus, represent an integral part of a healthy lifestyle.
In conclusion, the estimated intake of marine food pro-
ducts and EPA1DHA among adult Quebecers is much
lower than international recommendations. Since n-3 LC
PUFA confer health benefits and may reduce health costs,
strategies to increase their consumption should be imple-
mented to improve public health in Quebec.
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